Furthermore, in models of hyperlipidemia, pterostilbene increased expression of PPAR-γ, a target for lipid lowering agents, but exerted the opposite effect in AD models where it increased PPAR-α, a key modulator of neural antioxidant activity [79, 91]. Here, PPARA is linked to Alzheimer disease.